NA Colorectal Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Description

List of Tables

North America colorectal cancer diagnostics market is projected to register a substantial CAGR of 8.8% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.

Market Segmentation:

North America Colorectal Cancer Diagnostics, By Product Type (Instruments and Consumables & Accessories), Test Type (Stool Examination, Blood Test, Imaging Test, Tumor Markers, Biopsy, and Others), Stages (Stage 0, Stage I, Stage II, Stage III, and Stage IV), Cancer Type (Adenocarcinoma, Colorectal Lymphoma, Gastrointestinal Stromal Tumors, Carcinoid Tumors, and Others), Age Group (Geriatric, Adults, and Pediatric), End User (Hospital, Diagnostic Centers, Cancer Research Centers, Ambulatory Surgical Centers, Academic Institutes, and Others), Country (U.S., Canada, and Mexico) Industry Trends and Forecast to 2030.

Some of the factors that can affect the growth of the market are:

Rising preference for preventive health check-ups

Rising healthcare expenditure

Market Players:

The key market players in North America colorectal cancer diagnostics market are listed below:

F. Hoffmann-La Roche Ltd

Koninklijke Philips N.V.

Thermo Fisher Scientific Inc.

Illumina, Inc.

Quest Diagnostics Incorporated

CANON MEDICAL SYSTEMS CORPORATION.

Bio-Rad Laboratories, Inc.

Merck KGaA

FUJIFILM Corporation

Agilent Technologies, Inc.

Siemens Healthcare GmbH

Neusoft Corporation

BioFire Diagnostics

Myriad Genetics Inc.

QIAGEN

Hologic, Inc.

Time Medical Holding.

FONAR Corp.

PlexBio

MinFound Medical Systems Co., Ltd

FONAR, Corp.

1 INTRODUCTION 43

1.1 OBJECTIVES OF THE STUDY 43
1.2 MARKET DEFINITION 43
1.3 OVERVIEW OF THE NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET 43
1.4 LIMITATIONS 45
1.5 MARKETS COVERED 45

2 MARKET SEGMENTATION 48

2.1 MARKETS COVERED 48
2.2 GEOGRAPHICAL SCOPE 49
2.3 YEARS CONSIDERED FOR THE STUDY 50
2.4 CURRENCY AND PRICING 50
2.5 DBMR TRIPOD DATA VALIDATION MODEL 51
2.6 MULTIVARIATE MODELLING 54
2.7 PRODUCT TYPE LIFELINE CURVE 54
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 55
2.9 DBMR MARKET POSITION GRID 56
2.10 MARKET END USER COVERAGE GRID 57
2.11 VENDOR SHARE ANALYSIS 58
2.12 SECONDARY SOURCES 59
2.13 ASSUMPTIONS 59

3 EXECUTIVE SUMMARY 60

4 PREMIUM INSIGHTS 63

4.1 PORTER'S FIVE FORCES 64
4.2 PESTEL ANALYSIS 65

5 INDUSTRY INSIGHTS: 66

6 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, REGULATIONS 67

6.1 REGULATORY SCENARIO IN THE U.S 67
6.2 REGULATORY SCENARIO IN AUSTRALIA 67
6.3 REGULATORY SCENARIO IN JAPAN 68
6.4 REGULATORY SCENARIO IN CHINA 68

7 MARKET OVERVIEW 70

7.1 DRIVERS 72
- 7.1.1 GROWING PREVALENCE OF COLORECTAL CANCER 72
- 7.1.2 RISE IN THE NUMBER OF PATIENTS SUFFERING FROM DIVERTICULITIS AND ULCERATIVE COLITIS. 72
- 7.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 72
7.2 RESTRAINTS 73
- 7.2.1 STRINGENT REGULATORY POLICIES 73
- 7.2.2 HIGH COST FOR THE COLORECTAL CANCER TREATMENTS. 73
7.3 OPPORTUNITIES 74
- 7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 74
- 7.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 75
- 7.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 75
7.4 CHALLENGES 76
- 7.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 76
- 7.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 77

8 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 78

8.1 OVERVIEW 79
8.2 INSTRUMENTS 82
- 8.2.1 PATHOLOGY-BASED INSTRUMENTS 83
  - 8.2.1.1 PCR INSTRUMENTS 83
  - 8.2.1.2 SLIDE STAINING SYSTEMS 83
  - 8.2.1.3 TISSUE PROCESSING SYSTEMS 84
  - 8.2.1.4 CELL PROCESSORS 84
  - 8.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS 84
- 8.2.2 IMAGING INSTRUMENTS 84
  - 8.2.2.1 ULTRASOUND SYSTEMS 84
  - 8.2.2.2 CT SYSTEMS 84
  - 8.2.2.3 MRI SYSTEMS 85
  - 8.2.2.4 OTHERS 85
- 8.2.3 BIOPSY INSTRUMENTS 85
- 8.2.4 OTHERS 85
8.3 CONSUMABLES & ACCESSORIES 85
- 8.3.1 KITS 86
  - 8.3.1.1 PCR KITS 86
  - 8.3.1.2 DNA POLYMERASE KITS 86
  - 8.3.1.3 NUCLEIC ACID ISOLATION KITS 86
  - 8.3.1.4 OTHERS 87
- 8.3.2 REAGENTS 87
  - 8.3.2.1 ASSAYS 87
  - 8.3.2.2 BUFFERS 87
  - 8.3.2.3 PRIMERS 87
  - 8.3.2.4 OTHERS 87
- 8.3.3 OTHER CONSUMABLES 87

9 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE 88

9.1 OVERVIEW 89
9.2 STOOL EXAMINATION 92
9.3 BLOOD TEST 92
- 9.3.1 COMPLETE BLOOD COUNT (CBC) 93
- 9.3.2 TUMOR MARKER TEST 94
- 9.3.3 LIVER ENZYME BLOOD TEST 94
9.4 IMAGING TEST 94
- 9.4.1 COMPUTED TOMOGRAPHY (CT) SCAN 95
- 9.4.2 MRI 95
- 9.4.3 ULTRASOUND 95
- 9.4.4 POSITION EMISSION TOMOGRAPHY (PET) 96
- 9.4.5 OTHERS 96
9.5 TUMOR MARKERS 96
- 9.5.1 CARCINOEMBRYONIC ANTIGEN (CEA) 97
- 9.5.2 CA19-9 BIOMARKER TEST 97
- 9.5.3 CA 50 MARKER TEST 97
- 9.5.4 OTHERS 97
9.6 BIOPSY 97
9.7 OTHERS 98

10 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES 99

10.1 OVERVIEW 100
10.2 STAGE III 103
10.3 STAGE IV 103
10.4 STAGE II 104
10.5 STAGE I 105
10.6 STAGE 0 105

11 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP 107

11.1 OVERVIEW 108
11.2 GERIATRIC 111
11.3 ADULTS 111
11.4 PEDIATRIC 112

12 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 114

12.1 OVERVIEW 115
12.2 ADENOCARCINOMA 118
12.3 COLORECTAL LYMPHOMA 118
12.4 GASTROINTESTINAL STROMAL TUMORS 119
12.5 CARCINOID TUMORS 120
12.6 OTHERS 120

13 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER 122

13.1 OVERVIEW 123
13.2 HOSPITALS 126
13.3 DIAGNOSTIC CENTERS 126
13.4 CANCER RESEARCH CENTERS 127
13.5 AMBULATORY SURGICAL CENTERS 128
13.6 ACADEMIC INSTITUTES 128
13.7 OTHERS 129

14 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION 131

14.1 NORTH AMERICA 132
- 14.1.1 U.S. 141
- 14.1.2 CANADA 146
- 14.1.3 MEXICO 151

15 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 156

15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 156

16 SWOT ANALYSIS 157

17 COMPANY PROFILE 158

17.1 F. HOFFMANN- LA ROCHE LTD 158
- 17.1.1 COMPANY SNAPSHOT 158
- 17.1.2 REVENUE ANALYSIS 158
- 17.1.3 COMPANY SHARE ANALYSIS 159
- 17.1.4 PRODUCT PORTFOLIO 159
- 17.1.5 RECENT DEVELOPMENT 159
17.2 KONINKLIJKE PHILIPS N.V. 160
- 17.2.1 COMPANY SNAPSHOT 160
- 17.2.2 REVENUE ANALYSIS 160
- 17.2.3 COMPANY SHARE ANALYSIS 161
- 17.2.4 PRODUCT PORTFOLIO 161
- 17.2.5 RECENT DEVELOPMENT 161
17.3 THERMO FISHER SCIENTIFIC INC. 163
- 17.3.1 COMPANY SNAPSHOT 163
- 17.3.2 REVENUE ANALYSIS 163
- 17.3.3 COMPANY SHARE ANALYSIS 164
- 17.3.4 PRODUCT PORTFOLIO 164
- 17.3.5 RECENT DEVELOPMENT 164
17.4 ILLUMINA, INC. 165
- 17.4.1 COMPANY SNAPSHOT 165
- 17.4.2 REVENUE ANALYSIS 165
- 17.4.3 COMPANY SHARE ANALYSIS 166
- 17.4.4 PRODUCT PORTFOLIO 166
- 17.4.5 RECENT DEVELOPMENT 166
17.5 QUEST DIAGNOSTICS INCORPORATED 167
- 17.5.1 COMPANY SNAPSHOT 167
- 17.5.2 REVENUE ANALYSIS 167
- 17.5.3 COMPANY SHARE ANALYSIS 168
- 17.5.4 PRODUCT PORTFOLIO 168
- 17.5.5 RECENT DEVELOPMENT 168
17.6 ABBOTT 169
- 17.6.1 COMPANY SNAPSHOT 169
- 17.6.2 REVENUE ANALYSIS 169
- 17.6.3 PRODUCT PORTFOLIO 170
- 17.6.4 RECENT DEVELOPMENT 170
17.7 AGILENT TECHNOLOGIES, INC. 171
- 17.7.1 COMPANY SNAPSHOT 171
- 17.7.2 REVENUE ANALYSIS 171
- 17.7.3 PRODUCT PORTFOLIO 172
- 17.7.4 RECENT DEVELOPMENT 172
17.8 BD 173
- 17.8.1 COMPANY SNAPSHOT 173
- 17.8.2 REVENUE ANALYSIS 173
- 17.8.3 PRODUCT PORTFOLIO 174
- 17.8.4 RECENT DEVELOPMENT 174
17.9 BEIJING O&D BIOTECH CO., LTD. 175
- 17.9.1 COMPANY SNAPSHOT 175
- 17.9.2 PRODUCT PORTFOLIO 175
- 17.9.3 RECENT DEVELOPMENT 175
17.10 BIOFIRE DIAGNOSTICS 176
- 17.10.1 COMPANY SNAPSHOT 176
- 17.10.2 REVENUE ANALYSIS 176
- 17.10.3 PRODUCT PORTFOLIO 177
- 17.10.4 RECENT DEVELOPMENT 177
17.11 BIO-RAD LABORATORIES, INC. 178
- 17.11.1 COMPANY SNAPSHOT 178
- 17.11.2 REVENUE ANALYSIS 178
- 17.11.3 PRODUCT PORTFOLIO 179
- 17.11.4 RECENT DEVELOPMENT 179
17.12 CANON MEDICAL SYSTEMS CORPORATION. 180
- 17.12.1 COMPANY SNAPSHOT 180
- 17.12.2 REVENUE ANALYSIS 180
- 17.12.3 PRODUCT PORTFOLIO 181
- 17.12.4 RECENT DEVELOPMENT 181
17.13 FONAR CORP. 182
- 17.13.1 COMPANY SNAPSHOT 182
- 17.13.2 REVENUE ANALYSIS 182
- 17.13.3 PRODUCT PORTFOLIO 183
- 17.13.4 RECENT DEVELOPMENT 183
17.14 FUJIFILM CORPORATION 184
- 17.14.1 COMPANY SNAPSHOT 184
- 17.14.2 REVENUE ANALYSIS 184
- 17.14.3 PRODUCT PORTFOLIO 185
- 17.14.4 RECENT DEVELOPMENT 185
17.15 GE HEALTHCARE. 186
- 17.15.1 COMPANY SNAPSHOT 186
- 17.15.2 REVENUE ANALYSIS 186
- 17.15.3 PRODUCT PORTFOLIO 187
- 17.15.4 RECENT DEVELOPMENT 187
17.16 HOLOGIC, INC. 188
- 17.16.1 COMPANY SNAPSHOT 188
- 17.16.2 REVENUE ANALYSIS 188
- 17.16.3 PRODUCT PORTFOLIO 189
- 17.16.4 RECENT DEVELOPMENT 189
17.17 MEDONICA CO. LTD 190
- 17.17.1 COMPANY SNAPSHOT 190
- 17.17.2 PRODUCT PORTFOLIO 190
- 17.17.3 RECENT DEVELOPMENT 190
17.18 MERCK KGAA 191
- 17.18.1 COMPANY SNAPSHOT 191
- 17.18.2 REVENUE ANALYSIS 191
- 17.18.3 PRODUCT PORTFOLIO 192
- 17.18.4 RECENT DEVELOPMENT 192
17.19 MINFOUND MEDICAL SYSTEMS CO., LTD 193
- 17.19.1 COMPANY SNAPSHOT 193
- 17.19.2 PRODUCT PORTFOLIO 193
- 17.19.3 RECENT DEVELOPMENT 193
17.20 MYRIAD GENETICS, INC. 194
- 17.20.1 COMPANY SNAPSHOT 194
- 17.20.2 REVENUE ANALYSIS 194
- 17.20.3 PRODUCT PORTFOLIO 195
- 17.20.4 RECENT DEVELOPMENT 195
17.21 NEUSOFT CORPORATION 196
- 17.21.1 COMPANY SNAPSHOT 196
- 17.21.2 REVENUE ANALYSIS 196
- 17.21.3 PRODUCT PORTFOLIO 197
- 17.21.4 RECENT DEVELOPMENT 197
17.22 PLEXBIO 198
- 17.22.1 COMPANY SNAPSHOT 198
- 17.22.2 PRODUCT PORTFOLIO 198
- 17.22.3 RECENT DEVELOPMENT 198

17.23 QIAGEN 199
- 17.23.1 COMPANY SNAPSHOT 199
- 17.23.2 REVENUE ANALYSIS 199
- 17.23.3 PRODUCT PORTFOLIO 200
- 17.23.4 RECENT DEVELOPMENT 200
17.24 SIEMENS HEALTHCARE GMBH 201
- 17.24.1 COMPANY SNAPSHOT 201
- 17.24.2 REVENUE ANALYSIS 201
- 17.24.3 1.2.3 PRODUCT PORTFOLIO 202
- 17.24.4 RECENT DEVELOPMENT 202
17.25 STERNMED GMBH 203
- 17.25.1 COMPANY SNAPSHOT 203
- 17.25.2 PRODUCT PORTFOLIO 203
- 17.25.3 RECENT DEVELOPMENT 203
17.26 TIME MEDICAL HOLDING. 204
- 17.26.1 COMPANY SNAPSHOT 204
- 17.26.2 PRODUCT PORTFOLIO 204
- 17.26.3 RECENT DEVELOPMENT 204

18 QUESTIONNAIRE 205

19 RELATED REPORTS 208

LIST OF TABLES

TABLE 1 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 58
TABLE 2 NORTH AMERICA INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 59
TABLE 3 NORTH AMERICA INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 60
TABLE 4 NORTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 60
TABLE 5 NORTH AMERICA IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 61
TABLE 6 NORTH AMERICA CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 62
TABLE 7 NORTH AMERICA CONSUMABLES AND ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 63
TABLE 8 NORTH AMERICA KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 63
TABLE 9 NORTH AMERICA REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 64
TABLE 10 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 68
TABLE 11 NORTH AMERICA STOOL EXAMINATION IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 69
TABLE 12 NORTH AMERICA BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 70
TABLE 13 NORTH AMERICA BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 70
TABLE 14 NORTH AMERICA IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 72
TABLE 15 NORTH AMERICA IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 72
TABLE 16 NORTH AMERICA TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 73
TABLE 17 NORTH AMERICA TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 74
TABLE 18 NORTH AMERICA BIOPSY IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 75
TABLE 19 NORTH AMERICA OTHERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 75
TABLE 20 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION) 79
TABLE 21 NORTH AMERICA STAGE III IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 80
TABLE 22 NORTH AMERICA STAGE IV IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 81
TABLE 23 NORTH AMERICA STAGE II IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 81
TABLE 24 NORTH AMERICA STAGE I IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
TABLE 25 NORTH AMERICA STAGE 0 IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 83
TABLE 26 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 87
TABLE 27 NORTH AMERICA GERIATRIC IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 88
TABLE 28 NORTH AMERICA ADULTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 89
TABLE 29 NORTH AMERICA PEDIATRIC IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 90
TABLE 30 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 94
TABLE 31 NORTH AMERICA ADENOCARCINOMA IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 95
TABLE 32 NORTH AMERICA COLORECTAL LYMPHOMA IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 96
TABLE 33 NORTH AMERICA GASTROINTESTINAL STROMAL TUMORS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 96
TABLE 34 NORTH AMERICA CARCINOID TUMORS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 97
TABLE 35 NORTH AMERICA OTHERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 98
TABLE 36 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 102
TABLE 37 NORTH AMERICA HOSPITALS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 103
TABLE 38 NORTH AMERICA DIAGNOSTIC CENTERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 104
TABLE 39 NORTH AMERICA CANCER RESEARCH CENTERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 105
TABLE 40 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 105
TABLE 41 NORTH AMERICA ACADEMIC INSTITUTES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 106
TABLE 42 NORTH AMERICA OTHERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 107
TABLE 43 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 113
TABLE 44 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 113
TABLE 45 NORTH AMERICA INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 113
TABLE 46 NORTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 113
TABLE 47 NORTH AMERICA IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 114
TABLE 48 NORTH AMERICA CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 114
TABLE 49 NORTH AMERICA KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 114
TABLE 50 NORTH AMERICA REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 114
TABLE 51 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 115
TABLE 52 NORTH AMERICA BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 115
TABLE 53 NORTH AMERICA IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 115
TABLE 54 NORTH AMERICA TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 116
TABLE 55 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION) 116
TABLE 56 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 116
TABLE 57 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 117
TABLE 58 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 117
TABLE 59 U.S. COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 118
TABLE 60 U.S. INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 118
TABLE 61 U.S. PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 118
TABLE 62 U.S. IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 119
TABLE 63 U.S. CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 119
TABLE 64 U.S. KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 119
TABLE 65 U.S. REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 120
TABLE 66 U.S. COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 120
TABLE 67 U.S. BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 120
TABLE 68 U.S. IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 121
TABLE 69 U.S. TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 121
TABLE 70 U.S. COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION) 121
TABLE 71 U.S. COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 122
TABLE 72 U.S. COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 122
TABLE 73 U.S. COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 122
TABLE 74 CANADA COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 123
TABLE 75 CANADA INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 123
TABLE 76 CANADA PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 123
TABLE 77 CANADA IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 124
TABLE 78 CANADA CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 124
TABLE 79 CANADA KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 124
TABLE 80 CANADA REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 125
TABLE 81 CANADA COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 125
TABLE 82 CANADA BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 125
TABLE 83 CANADA IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 126
TABLE 84 CANADA TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 126
TABLE 85 CANADA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION) 126
TABLE 86 CANADA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 127
TABLE 87 CANADA COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 127
TABLE 88 CANADA COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 127
TABLE 89 MEXICO COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 128
TABLE 90 MEXICO INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 128
TABLE 91 MEXICO PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 128
TABLE 92 MEXICO IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 129
TABLE 93 MEXICO CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 129
TABLE 94 MEXICO KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 129
TABLE 95 MEXICO REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 129
TABLE 96 MEXICO COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 130
TABLE 97 MEXICO BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 130
TABLE 98 MEXICO IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 130
TABLE 99 MEXICO TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 131
TABLE 100 MEXICO COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION) 131
TABLE 101 MEXICO COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 131
TABLE 102 MEXICO COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 132
TABLE 103 MEXICO COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 132

LIST OF FIGURES

FIGURE 1 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: SEGMENTATION 23
FIGURE 2 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION 26
FIGURE 3 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: DROC ANALYSIS 27
FIGURE 4 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 28
FIGURE 5 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 28
FIGURE 6 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 30
FIGURE 7 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 31
FIGURE 8 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID 32
FIGURE 9 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 33
FIGURE 10 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: SEGMENTATION 37
FIGURE 11 THE INCREASE IN THE AWARENESS ABOUT COLORECTAL CANCER IS EXPECTED TO DRIVE THE NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET GROWTH IN THE FORECAST PERIOD 38
FIGURE 12 THE INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET IN 2023 & 2030 38
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET 46
FIGURE 14 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022 54
FIGURE 15 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION) 55
FIGURE 16 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030) 55
FIGURE 17 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE 56
FIGURE 18 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022 64
FIGURE 19 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION) 65
FIGURE 20 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030) 65
FIGURE 21 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE 66
FIGURE 22 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, 2022 75
FIGURE 23 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, 2023-2030 (USD MILLION) 76
FIGURE 24 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, CAGR (2023-2030) 76
FIGURE 25 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, LIFELINE CURVE 77
FIGURE 26 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2022 83
FIGURE 27 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION) 84
FIGURE 28 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030) 84
FIGURE 29 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE 85
FIGURE 30 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022 90
FIGURE 31 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION) 91
FIGURE 32 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030) 91
FIGURE 33 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE 92
FIGURE 34 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY END USER, 2022 98
FIGURE 35 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION) 99
FIGURE 36 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030) 99
FIGURE 37 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 100
FIGURE 38 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 108
FIGURE 39 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 109
FIGURE 40 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 109
FIGURE 41 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 110
FIGURE 42 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030) 110
FIGURE 43 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 131